DEA faces scrutiny over fentanyl flow in New Mexico

Current and former Drug Enforcement Administration agents say the agency failed to stop a significant flow of fentanyl pills into New Mexico over a two-year period, according to records reviewed by the Associated Press.

The agents, who spoke on condition of anonymity, did not specify how many individuals shared these views or provide details about their positions or tenure. They characterized the DEA's response to the fentanyl distribution as insufficient.

The AP reviewed records related to the case but did not make public the nature or scope of those records. The news organization did not disclose what specific enforcement actions agents said the DEA failed to take or what alternative steps they believed the agency should have pursued.

The fentanyl pills in question reached New Mexico streets between 2023 and 2025, according to the agents' accounts. They did not specify the exact quantity or identify specific geographic areas within the state.

The DEA did not respond to requests for comment about the allegations. A spokesperson for the agency did not provide a statement addressing the claims or explaining the agency's approach to fentanyl enforcement during the period in question.

The inability to identify specific agents or their roles limits verification of their accounts. The AP did not report whether the agents had direct knowledge of enforcement decisions, access to operational files, or other basis for their conclusions about agency actions.

New Mexico has experienced significant opioid-related deaths in recent years. Federal data shows fentanyl availability has increased nationwide, though the AP did not establish a direct causal link between the alleged DEA inaction and overdose trends in the state.

Fentanyl enforcement remains a priority for federal drug agencies. The DEA has not disclosed its specific strategies for halting pill distribution or the resources it allocated to New Mexico operations during the period the agents referenced.